Close Menu

NEW YORK – Agilent Technologies announced today that it has priced an underwritten, registered public offering of a series of its senior notes, in an aggregate principal amount of $500 million.

In a filing with the US Securities and Exchange Commission, the company said that the notes will mature in September 2029 and will bear interest at an annual rate of 2.750 percent. The offering is expected to close on Sep. 16, and Agilent is expecting net proceeds of approximately $492.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.